<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11687">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954796</url>
  </required_header>
  <id_info>
    <org_study_id>SGN352-001</org_study_id>
    <nct_id>NCT02954796</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the safety of a drug called SGN-CD352A, to find out what its side effects
      are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple
      myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will have 2 parts. In the first part, different doses of SGN-CD352A will be given
      to different patients (each individual patient will get the same dose for all treatments).
      The doses will be very low at the start of the trial, and will increase only when the lower
      dose levels are proven safe.

      In the second part of the study, up to 2 dose levels that are both safe and show promising
      activity against MM will be given to more patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type, incidence, severity, seriousness, and relatedness of adverse events (including laboratory abnormalities)</measure>
    <time_frame>Through 1 month following last dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicity</measure>
    <time_frame>During Cycle 1 (Trial Days 1-28)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete response</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies (ATA)</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD352A and metabolites</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory biomarkers of SGN CD352A- mediated pharmacodynamic effects</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CD352 characterization on malignant plasma cells</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>(Dose Escalation) Cohort 1 - 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD352A</intervention_name>
    <description>On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort 1 (8 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.</description>
    <arm_group_label>(Dose Escalation) Cohort 1 - 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of MM requiring systemic therapy (per the International Myeloma Working
             Group [IMWG] ).

          -  Age 18 years or older.

          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.

          -  Life expectancy greater than months.

          -  Received at least 2 prior lines of therapy for MM including an immunomodulatory drug
             and a proteasome inhibitor.

          -  Measurable disease, as defined by at least one of the following: Serum M protein 0.5
             g/dL or higher, Urine M protein 200 mg/24 hr or higher, Abnormal serum free light
             chain (SFLC) ratio.

          -  Adequate hematologic, renal, and hepatic function

          -  A negative pregnancy test (for females of childbearing potential).

          -  Patients must provide written informed consent.

        Exclusion Criteria:

          -  Other invasive malignancy within the past 3 years.

          -  Active cerebral/meningeal disease related to the underlying malignancy.

          -  Active Grade 3 or higher infection.

          -  Known to be positive for HIV or known to have active hepatitis B or C.

          -  Previous allogeneic stem cell transplant.

          -  Idiopathic interstitial pneumonia or impaired diffusion capacity of the lung for
             carbon monoxide (DLCO).

          -  Cerebrovascular or cardiovascular event, or congestive heart failure within the last
             6 months.

          -  Females who are pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Campbell, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Soon</last_name>
      <phone>626-256-4673</phone>
      <email>jsoon@coh.org</email>
    </contact>
    <contact_backup>
      <last_name>Lupe Duarte</last_name>
      <phone>626-256-3968</phone>
      <email>lduarte@coh.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amrita Krishnan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Harding</last_name>
      <phone>314-362-3515</phone>
      <email>mharding@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Schroeder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura McBride</last_name>
      <phone>551-996-8020</phone>
      <email>Laura.McBride@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>David Siegel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Glickman</last_name>
      <phone>646-962-9338</phone>
      <email>sog2010@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julia Kelman</last_name>
      <phone>646-962-9338</phone>
      <email>juk2025@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ruben Niesvizky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tenzin Tsomo</last_name>
      <phone>206-386-6000</phone>
      <email>tenzin.tsomo@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Alex Brooks</last_name>
      <phone>206-386-6000</phone>
      <email>alex.brooks@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Bensinger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hou</last_name>
      <phone>206-667-5010</phone>
      <email>khou@fredhutch.org</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Geoghegan</last_name>
      <phone>206-667-1426</phone>
      <email>jgeogheg@fredhutch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Damian Green</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>October 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
